Collectively, our findings show that the combination of cilengitide and EGFR inhibitors could represent a new chemotherapeutic option for modulating growth and invasive changes in EMT-associated NSCLC cell changes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.